Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Town Hall Provides Tools to Guide Patients Unsure About COVID-19 Vaccination

Ruth Jessen Hickman, MD  |  June 21, 2021

You may mention the new vaccines were subjected to all the typical steps in vaccine development and evaluation, including phase 1, 2 and 3 clinical trials. Don’t assume your patient knows what that means. Provide an explanation:

“That means studies were conducted in people, not just animals, beginning with tests in a few healthy volunteers (under a hundred) and moving up to large-scale tests in people with the disease (hundreds to thousands) to ensure the vaccine is safe and works as intended. The vaccines are safe. More than 302 million people in the U.S. have now been vaccinated, with rare serious side effects and very few deaths—about 7 per 1 million vaccinated women between 18 and 49 years old—positively linked to vaccination.”1

Dr. Chris Phillips

Dr. Phillips

“I think that when we start really respecting our patients [and giving them] the science,” says Dr. Manning, “you’ll be surprised at how many people will respond and say, ‘That makes sense.’”

Counter Patient Concerns
For some patients, statistics may be a helpful tool, noted co-moderator Chris Phillips, MD, of Paducah Rheumatology, Kentucky. For example, Dr. Philips said he might contrast the small risks of thrombosis from the Johnson & Johnson vaccine with the much greater risks of mortality from COVID-19, using specific numbers. “Sometimes I think our patients … misvalue how likely those things are to happen, so trying to recenter that is sometimes helpful,” he said.

Dr. David Karp

Dr. Karp

Another co-moderator, ACR President David R. Karp, MD, PhD, chief of the Rheumatic Diseases Division at UT Southwestern Medical Center, Dallas, remarked on a particular concern that many rheumatology patients have: the risk the vaccine may trigger a flare. “I tell patients that if you have a flare [after a vaccine], we can treat you, but in the meantime, you are protected from a disease that is deadly. Thus far, thousands of patients with rheumatic and autoimmune diseases have been vaccinated and have done well,” Dr. Karp said.

Sometimes, clinicians feel an urgency to get their patients vaccinated as quickly as possible, Dr. Manning noted. But by trying to understand patients’ specific concerns and gently and repeatedly bringing up the subject, clinicians may gradually make an impact. “Yes, there is urgency when it comes to being vaccinated for COVID, but if you don’t keep trying to plant the seed and keep the trust open, we definitely aren’t going to get there,” she said.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:American College of Rheumatology Tagged with:COVID-19vaccination

Related Articles

    Vax Hesitancy? Myths & Facts for Patients

    December 16, 2021

    Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

    Dusan Petkovic / shutterstock.com

    COVID-19 Vaccination in Patients with Rheumatic Disease

    August 11, 2021

    With a large percentage of the U.S. population unsure whether they will get vaccinated against COVID-19, rheumatology patients remain vulnerable. On May 13, the ACR hosted a virtual town hall highlighting ways rheuma­tology providers might effectively approach their patients who have not yet decided to get a COVID-19 vaccine. Get the Slow Yes At the…

    The End of the Beginning: COVID-19 Vaccines & Other Conundrums

    December 9, 2020

    “It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEAfter some fits and starts, I finally struck…

    Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

    July 6, 2021

    Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences